标题
Diabetes Drug Effects on the Skeleton
作者
关键词
Diabetes, Fracture, BMD, Anti-diabetes treatment, Bone turnover markers, Diabetes drugs, Bone
出版物
CALCIFIED TISSUE INTERNATIONAL
Volume 100, Issue 2, Pages 133-149
出版商
Springer Nature
发表日期
2016-11-04
DOI
10.1007/s00223-016-0203-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES
- (2016) Matthew P. Gilbert et al. Endocrine Practice
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Risk of fractures and diabetes medications: a nationwide cohort study
- (2016) H. J. Choi et al. OSTEOPOROSIS INTERNATIONAL
- Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
- (2015) Ofri Mosenzon et al. DIABETES CARE
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats
- (2014) Lorenzo Glorie et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
- (2014) Zhong-Ning Zhu et al. BONE
- PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity
- (2014) Jessal J. Patel et al. CELL BIOCHEMISTRY AND FUNCTION
- Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin
- (2014) Rao N.V.S. Mamidi et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Fracture risk in diabetic elderly men: the MrOS study
- (2014) Nicola Napoli et al. DIABETOLOGIA
- Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
- (2014) Agata Ptaszynska et al. DRUG SAFETY
- Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells
- (2014) María Laura Sbaraglini et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats
- (2014) Justyna Fronczek-Sokół et al. Pharmacological Reports
- Successful Integration of Nonclinical and Clinical Findings in Interpreting the Clinical Relevance of Rodent Neoplasia with a New Chemical Entity
- (2014) Kirk Ways et al. TOXICOLOGIC PATHOLOGY
- Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione
- (2013) T. Cusick et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: Preventive effects of metformin
- (2013) María José Tolosa et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes
- (2013) Emily Jane Gallagher et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
- (2013) Boaz Hirshberg et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Sulfonylureas and Risk of Falls and Fractures: A Systematic Review
- (2013) Kate L. Lapane et al. DRUGS & AGING
- Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Prevents Osteopenia by Promoting Bone Formation and Suppressing Bone Resorption in Aged Ovariectomized Rats
- (2013) Xue Ma et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study
- (2013) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus
- (2013) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor
- (2013) Guillaume Mabilleau et al. JOURNAL OF ENDOCRINOLOGY
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes
- (2013) Ju-Young Kim et al. LIFE SCIENCES
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing
- (2013) J. Jeyabalan et al. OSTEOPOROSIS INTERNATIONAL
- Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials (胰高血糖素样肽-1受体激动剂的使用与骨折的关系：一项对随机临床试验的meta分析)
- (2013) Guillaume Mabilleau et al. Journal of Diabetes
- Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line
- (2013) M. Salai et al. Bone & Joint Journal
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
- (2012) H. M. Colhoun et al. DIABETOLOGIA
- Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus
- (2012) A H van Lierop et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Thiazolidinediones Induce Osteocyte Apoptosis by a G Protein-coupled Receptor 40-dependent Mechanism
- (2012) Aleksandra Mieczkowska et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice
- (2012) Chun Wang et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Protective Effect of Metformin on Periapical Lesions in Rats by Decreasing the Ratio of Receptor Activator of Nuclear Factor Kappa B Ligand/Osteoprotegerin
- (2012) Lingshuang Liu et al. JOURNAL OF ENDODONTICS
- Effect of pioglitazone on transdifferentiation of preosteoblasts from rat bone mesenchymal stem cells into adipocytes
- (2012) Linfang Wang et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption
- (2012) Eui-Sic Cho et al. MOLECULES AND CELLS
- The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes
- (2012) George R. Beck et al. Translational Research
- Role of sodium-glucose transporters in glucose uptake of the intestine and kidney
- (2012) Norio Harada et al. Journal of Diabetes Investigation
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials
- (2011) M. Monami et al. DIABETES CARE
- A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 d
- (2011) J. L. C. Borges et al. DIABETES OBESITY & METABOLISM
- Weight-loss-associated changes in bone mineral density and bone turnover after partial weight regain with or without aerobic exercise in obese women
- (2011) P S Hinton et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats
- (2011) Claudia Sedlinsky et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Rosiglitazone and Pioglitazone Inhibit Estrogen Synthesis in Human Granulosa Cells by Interfering with Androgen Binding to Aromatase
- (2011) D. Seto-Young et al. HORMONE AND METABOLIC RESEARCH
- AICAR, a Small Chemical Molecule, Primes Osteogenic Differentiation of Adult Mesenchymal Stem Cells
- (2011) Wei Wu et al. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
- Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats
- (2011) Qi-Guang Mai et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Rosiglitazone Decreases Bone Mass and Bone Marrow Fat
- (2011) Torben Harsløf et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Extrapancreatic roles of glimepiride on osteoblasts from rat manibular bone in vitro: Regulation of cytodifferentiation through PI3-kinases/Akt signalling pathway
- (2010) Pan Ma et al. ARCHIVES OF ORAL BIOLOGY
- The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled Trial
- (2010) Ugis Gruntmanis et al. CALCIFIED TISSUE INTERNATIONAL
- Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
- (2010) M. C. Bunck et al. DIABETES OBESITY & METABOLISM
- Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression
- (2010) G. Mabilleau et al. DIABETIC MEDICINE
- Differential Effects of PPAR-γ ActivationversusChemical or Genetic Reduction of DPP-4 Activity on Bone Quality in Mice
- (2010) Kimberly A. Kyle et al. ENDOCRINOLOGY
- Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats
- (2010) Ying Gao et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus
- (2010) Ippei Kanazawa et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor
- (2010) Bernardo Nuche-Berenguer et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus
- (2010) Zeina A. Habib et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus
- (2010) I. Kanazawa et al. OSTEOPOROSIS INTERNATIONAL
- Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow
- (2009) C. Sanz et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Thiazolidinediones and Fractures in Men and Women
- (2009) Colin R. Dormuth et al. ARCHIVES OF INTERNAL MEDICINE
- Four-month treatment with GLP-2 significantly increases hip BMD
- (2009) Dennis B. Henriksen et al. BONE
- Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States
- (2009) Bernardo Nuche-Berenguer et al. CALCIFIED TISSUE INTERNATIONAL
- Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis
- (2009) B. Gustafson et al. DIABETOLOGIA
- Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
- (2009) John Dormandy et al. DRUG SAFETY
- Effect of metformin on bone marrow progenitor cell differentiation: In vivo and in vitro studies
- (2009) M Silvina Molinuevo et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Osteoblast differentiation is functionally associated with decreased AMP kinase activity
- (2009) Takayuki Kasai et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes
- (2009) Daniel H. Solomon et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
- (2009) Bernard Zinman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Metformin reverses the deleterious effects of high glucose on osteoblast function
- (2009) Donghu Zhen et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway
- (2009) Pan Ma et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Use of Thiazolidinediones and Fracture Risk
- (2008) Christian Meier et al. ARCHIVES OF INTERNAL MEDICINE
- Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression
- (2008) Ippei Kanazawa et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism
- (2008) D. Naot et al. BONE
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
- (2008) Y. K. Loke et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Metformin Reverts Deleterious Effects of Advanced Glycation End-Products (AGEs) on Osteoblastic Cells
- (2008) L. Schurman et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study
- (2008) L Joseph Melton et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial
- (2008) Dorte Glintborg et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
- (2007) Chizumi Yamada et al. ENDOCRINOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started